Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects.

Clump DA, Pickering CR, Skinner HD.

Clin Cancer Res. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-3078. [Epub ahead of print]

PMID:
30413524
2.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.

Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A.

Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. Epub 2018 Oct 6.

PMID:
30291796
3.

Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.

Wangaryattawanich P, Branstetter BF 4th, Hughes M, Clump DA 2nd, Heron DE, Rath TJ.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1884-1888. doi: 10.3174/ajnr.A5767. Epub 2018 Aug 30.

PMID:
30166429
4.

Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.

Sutera P, Clump DA, Kalash R, D'Ambrosio D, Mihai A, Wang H, Petro DP, Burton SA, Heron DE.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):116-122. doi: 10.1016/j.ijrobp.2018.08.027. Epub 2018 Aug 25.

PMID:
30149056
5.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13.

6.

Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field.

Horne ZD, Dohopolski MJ, Clump DA, Burton SA, Heron DE.

Pract Radiat Oncol. 2018 May - Jun;8(3):e117-e123. doi: 10.1016/j.prro.2017.11.011. Epub 2017 Dec 8.

PMID:
29724402
7.

Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.

Kim H, Vargo JA, Beriwal S, Clump DA, Ohr JP, Ferris RL, Heron DE, Huq MS, Smith KJ.

Head Neck. 2018 Aug;40(8):1743-1751. doi: 10.1002/hed.25142. Epub 2018 Mar 14.

PMID:
29537684
8.

Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group.

Vargo JA, Moiseenko V, Grimm J, Caudell J, Clump DA, Yorke E, Xue J, Vinogradskiy Y, Moros EG, Mavroidis P, Jain S, El Naqa I, Marks LB, Heron DE.

Int J Radiat Oncol Biol Phys. 2018 Jan 31. pii: S0360-3016(18)30107-X. doi: 10.1016/j.ijrobp.2018.01.044. [Epub ahead of print]

PMID:
29477291
9.

Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy.

Gebhardt BJ, Vargo JA, Ling D, Jones B, Mohney M, Clump DA, Ohr JP, Ferris RL, Heron DE.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):195-200. doi: 10.1016/j.ijrobp.2017.11.045. Epub 2017 Dec 5.

PMID:
29398127
10.

Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.

Horne ZD, Richman AH, Dohopolski MJ, Clump DA, Burton SA, Heron DE.

Lung Cancer. 2018 Jan;115:1-4. doi: 10.1016/j.lungcan.2017.10.014. Epub 2017 Nov 10.

PMID:
29290248
11.

Role of Immunotherapy in Head and Neck Cancer.

Ling DC, Bakkenist CJ, Ferris RL, Clump DA.

Semin Radiat Oncol. 2018 Jan;28(1):12-16. doi: 10.1016/j.semradonc.2017.08.009. Review.

PMID:
29173750
12.

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL.

Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.

13.

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.

14.

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.

Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, Anderson CJ, Edwards WB, Ferris RL.

Oncoimmunology. 2017 May 19;6(7):e1329071. doi: 10.1080/2162402X.2017.1329071. eCollection 2017.

15.

Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-risk Primary Salivary Gland Malignancies.

Gebhardt BJ, Ohr JP, Ferris RL, Duvvuri U, Kim S, Johnson JT, Heron DE, Clump DA 2nd.

Am J Clin Oncol. 2018 Sep;41(9):888-893. doi: 10.1097/COC.0000000000000386.

PMID:
28394767
16.

Online palliative care and oncology patient education resources through Google: Do they meet national health literacy recommendations?

Prabhu AV, Crihalmeanu T, Hansberry DR, Agarwal N, Glaser C, Clump DA, Heron DE, Beriwal S.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):306-310. doi: 10.1016/j.prro.2017.01.013. Epub 2017 Jan 27.

PMID:
28341318
17.

Salvage stereotactic radiosurgery for recurrent glioblastoma multiforme with prior radiation therapy.

Holt DE, Bernard ME, Quan K, Clump DA, Engh JA, Burton SA, Heron DE.

J Cancer Res Ther. 2016 Oct-Dec;12(4):1243-1248. doi: 10.4103/0973-1482.199537.

18.

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.

Vendetti FP, Leibowitz BJ, Barnes J, Schamus S, Kiesel BF, Abberbock S, Conrads T, Clump DA, Cadogan E, O'Connor MJ, Yu J, Beumer JH, Bakkenist CJ.

Sci Rep. 2017 Feb 1;7:41892. doi: 10.1038/srep41892.

19.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.

20.

Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiation.

Ling DC, Chapman BV, Kim J, Choby GW, Kabolizadeh P, Clump DA, Ferris RL, Kim S, Beriwal S, Heron DE, Duvvuri U.

Oral Oncol. 2016 Oct;61:41-6. doi: 10.1016/j.oraloncology.2016.08.004. Epub 2016 Aug 25.

PMID:
27688103
21.

Radiation Oncology and Online Patient Education Materials: Deviating From NIH and AMA Recommendations.

Prabhu AV, Hansberry DR, Agarwal N, Clump DA, Heron DE.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):521-8. doi: 10.1016/j.ijrobp.2016.06.2449. Epub 2016 Jun 25.

PMID:
27681748
22.

Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Albergotti WG, Davis KS, Abberbock S, Bauman JE, Ohr J, Clump DA, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL.

Oral Oncol. 2016 Sep;60:55-60. doi: 10.1016/j.oraloncology.2016.07.003. Epub 2016 Jul 7. Review.

23.

Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer.

Ling DC, Vargo JA, Ferris RL, Ohr J, Clump DA, Yau WW, Duvvuri U, Kim S, Johnson JT, Bauman JE, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):973-980. doi: 10.1016/j.ijrobp.2016.02.049.

PMID:
27302512
24.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

25.

Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas.

Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, Clump DA, Heron DE, Beriwal S.

Cancer. 2016 Jul 1;122(13):2021-30. doi: 10.1002/cncr.30021. Epub 2016 Apr 25.

26.

Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma.

Quan K, Xu KM, Zhang Y, Clump DA, Flickinger JC, Lalonde R, Burton SA, Heron DE.

Semin Radiat Oncol. 2016 Apr;26(2):112-9. doi: 10.1016/j.semradonc.2015.11.007. Epub 2015 Nov 27. Review.

PMID:
27000507
27.

Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival.

Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S.

Head Neck. 2016 Apr;38 Suppl 1:E2083-90. doi: 10.1002/hed.24384. Epub 2016 Feb 19.

PMID:
26894506
28.

Hyalinizing Clear Cell Carcinoma with Biopsy-Proven Spinal Metastasis: Case Report and Review of Literature.

Newman WC, Williams L, Duvvuri U, Clump DA 2nd, Amankulor N.

World Neurosurg. 2016 Jun;90:699.e7-699.e10. doi: 10.1016/j.wneu.2016.02.001. Epub 2016 Feb 6. Review.

PMID:
26862022
29.

Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer.

Davis KS, Lim CM, Clump DA, Heron DE, Ohr JP, Kim S, Duvvuri U, Johnson JT, Ferris RL.

Head Neck. 2016 Apr;38 Suppl 1:E1613-7. doi: 10.1002/hed.24287. Epub 2015 Dec 17.

30.

Treatment Plan Technique and Quality for Single-Isocenter Stereotactic Ablative Radiotherapy of Multiple Lung Lesions with Volumetric-Modulated Arc Therapy or Intensity-Modulated Radiosurgery.

Quan K, Xu KM, Lalonde R, Horne ZD, Bernard ME, McCoy C, Clump DA, Burton SA, Heron DE.

Front Oncol. 2015 Oct 6;5:213. doi: 10.3389/fonc.2015.00213. eCollection 2015.

31.

Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and i(125) vicryl mesh brachytherapy.

Gill BS, Clump DA, Burton SA, Christie NA, Schuchert MJ, Heron DE.

Front Oncol. 2015 May 11;5:109. doi: 10.3389/fonc.2015.00109. eCollection 2015.

32.

Cancer of the oropharynx.

Clump DA, Bauman JE, Ferris RL.

Surg Oncol Clin N Am. 2015 Jul;24(3):509-20. doi: 10.1016/j.soc.2015.03.014. Epub 2015 Apr 15. Review.

PMID:
25979397
33.

Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis.

Holt DE, Gill BS, Clump DA, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE.

Front Oncol. 2015 Apr 8;5:84. doi: 10.3389/fonc.2015.00084. eCollection 2015.

34.

Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy.

Xu KM, Quan K, Clump DA, Ferris RL, Heron DE.

Front Oncol. 2015 Mar 17;5:65. doi: 10.3389/fonc.2015.00065. eCollection 2015.

35.

A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri U, Kim S, Johnson JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):480-8. doi: 10.1016/j.ijrobp.2014.11.023. Epub 2015 Jan 30.

PMID:
25680594
36.

Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history.

Davis KS, Vargo JA, Ferris RL, Burton SA, Ohr JP, Clump DA, Heron DE.

Oral Oncol. 2014 Nov;50(11):1104-8. doi: 10.1016/j.oraloncology.2014.08.004. Epub 2014 Aug 28.

37.

Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer.

Vargo JA, Ferris RL, Clump DA, Heron DE.

Front Oncol. 2014 Aug 11;4:214. doi: 10.3389/fonc.2014.00214. eCollection 2014.

38.

Pretreatment SUVmax as a Marker for Progression-Free Survival in Stage I NSCLC Treated With SBRT.

Horne ZD, Clump DA, Shah S, Vargo JA, Burton SA, Christie NA, Schuchert MJ, Landreneau RJ, Luketich JD, Heron DE.

Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S3-4. doi: 10.1016/j.prro.2013.01.014. Epub 2013 Mar 25. No abstract available.

PMID:
24674539
39.

Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE.

Radiat Oncol. 2014 Jan 30;9:41. doi: 10.1186/1748-717X-9-41.

40.

Extent of perilesional edema differentiates radionecrosis from tumor recurrence following stereotactic radiosurgery for brain metastases.

Leeman JE, Clump DA, Flickinger JC, Mintz AH, Burton SA, Heron DE.

Neuro Oncol. 2013 Dec;15(12):1732-8. doi: 10.1093/neuonc/not130.

41.

Adjuvant stereotactic body radiotherapy┬▒cetuximab following salvage surgery in previously irradiated head and neck cancer.

Vargo JA, Kubicek GJ, Ferris RL, Duvvuri U, Johnson JT, Ohr J, Clump DA, Burton S, Heron DE.

Laryngoscope. 2014 Jul;124(7):1579-84. doi: 10.1002/lary.24441. Epub 2014 Apr 22.

PMID:
24123056
42.

Radiation therapy induces the DNA damage response in peripheral blood.

Bakkenist CJ, Czambel RK, Clump DA, Greenberger JS, Beumer JH, Schmitz JC.

Oncotarget. 2013 Aug;4(8):1143-8.

43.

Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation.

Wang K, Heron DE, Clump DA, Flickinger JC, Kubicek GJ, Rwigema JC, Ferris RL, Ohr JP, Quinn AE, Ozhasoglu C, Branstetter BF.

Radiother Oncol. 2013 Jan;106(1):90-5. doi: 10.1016/j.radonc.2012.11.008. Epub 2013 Jan 17.

PMID:
23333021
44.

Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors.

Lim CM, Clump DA, Heron DE, Ferris RL.

Oral Oncol. 2013 May;49(5):401-6. doi: 10.1016/j.oraloncology.2012.12.009. Epub 2013 Jan 16. Review.

PMID:
23332685
45.

Stereotactic radiosurgery for the treatment and palliation of base of skull metastases.

Clump DA, Leeman JE, Wegner RE, Burton SA, Mintz AH, Heron DE.

J Radiosurg SBRT. 2013;2(3):217-223.

46.

Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases.

Leeman JE, Clump DA, Wegner RE, Heron DE, Burton SA, Mintz AH.

Radiat Oncol. 2012 Jul 11;7:107. doi: 10.1186/1748-717X-7-107.

47.

Fractionated stereotactic radiosurgery for the treatment of meningiomas.

Bria C, Wegner RE, Clump DA, Vargo JA, Mintz AH, Heron DE, Burton SA.

J Cancer Res Ther. 2011 Jan-Mar;7(1):52-7. doi: 10.4103/0973-1482.80462.

48.

A Polymorphic Variant of AFAP-110 Enhances cSrc Activity.

Clump DA, Yu JJ, Cho Y, Gao R, Jett J, Zot H, Cunnick JM, Snyder B, Clump AC, Dodrill M, Gannett P, Coad JE, Shurina R, Figg WD, Reed E, Flynn DC.

Transl Oncol. 2010 Aug 1;3(4):276-85.

49.

c-Yes response to growth factor activation.

Clump DA, Qazi IH, Sudol M, Flynn DC.

Growth Factors. 2005 Dec;23(4):263-72. Review.

PMID:
16338789
50.

Protein expression levels of the Src activating protein AFAP are developmentally regulated in brain.

Clump DA, Clem R, Qian Y, Guappone-Koay A, Berrebi AS, Flynn DC.

J Neurobiol. 2003 Feb 15;54(3):473-85.

Supplemental Content

Loading ...
Support Center